Pacira BioSciences, Inc.
PCRX
$25.41
-$0.43-1.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 181.10M | 168.92M | 187.25M | 168.57M | 178.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 181.10M | 168.92M | 187.25M | 168.57M | 178.02M |
| Cost of Revenue | 43.27M | 36.55M | 63.78M | 57.97M | 46.19M |
| Gross Profit | 137.83M | 132.38M | 123.47M | 110.61M | 131.84M |
| SG&A Expenses | 88.58M | 86.78M | 79.61M | 74.33M | 68.13M |
| Depreciation & Amortization | 14.32M | 14.32M | 14.32M | 14.32M | 14.32M |
| Other Operating Expenses | -- | 351.00K | -- | -- | -- |
| Total Operating Expenses | 171.97M | 161.10M | 157.72M | 146.62M | 147.05M |
| Operating Income | 9.13M | 7.83M | 29.53M | 21.95M | 30.98M |
| Income Before Tax | -1.93M | 8.71M | 25.53M | -138.86M | 36.58M |
| Income Tax Expenses | 2.92M | 3.89M | 9.49M | 4.61M | 17.70M |
| Earnings from Continuing Operations | -4.85M | 4.81M | 16.04M | -143.47M | 18.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.85M | 4.81M | 16.04M | -143.47M | 18.89M |
| EBIT | 9.13M | 7.83M | 29.53M | 21.95M | 30.98M |
| EBITDA | 36.46M | 28.99M | 50.78M | 42.20M | 49.84M |
| EPS Basic | -0.11 | 0.10 | 0.35 | -3.11 | 0.41 |
| Normalized Basic EPS | -0.02 | 0.14 | 0.41 | 0.31 | 0.43 |
| EPS Diluted | -0.11 | 0.10 | 0.33 | -3.11 | 0.39 |
| Normalized Diluted EPS | -0.02 | 0.14 | 0.39 | 0.31 | 0.39 |
| Average Basic Shares Outstanding | 45.46M | 46.28M | 46.17M | 46.13M | 46.17M |
| Average Diluted Shares Outstanding | 45.46M | 46.53M | 49.04M | 46.13M | 50.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |